gefitinib

September 18, 2017September 18, 2017

AstraZeneca’s Tagrisso a Potential New Standard of Care in EGFR-mutated Lung Cancer

Lung Cancer, News

Results of a Phase 3 trial support the use of Tagrisso (osimertinib) as a new standard of care in the first-line treatment of patients with epidermal growth factor receptor-mutated (EGFRm) ... Read more

December 28, 2015December 28, 2015

Afatinib Appears To Be Better First-Line Option For EGFR-mutated Lung Cancer

Lung Cancer, News

According to clinical results recently presented at the ESMO Asia 2015 Congress in Singapore, patients with EGFR-activating mutations in advanced lung cancer have more clinical benefits from being treated with ... Read more

July 14, 2015July 14, 2015

Iressa (gefitinib) Now FDA-Approved for Metastatic Lung Cancer

Lung Cancer, News

Iressa (gefitinib) by AstraZeneca Pharmaceuticals will soon be available as another first-line treatment option for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are composed of certain types of epidermal ... Read more